1517 related articles for article (PubMed ID: 28163062)
1. Genome-Wide Association Study Identifies TLL1 Variant Associated With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection.
Matsuura K; Sawai H; Ikeo K; Ogawa S; Iio E; Isogawa M; Shimada N; Komori A; Toyoda H; Kumada T; Namisaki T; Yoshiji H; Sakamoto N; Nakagawa M; Asahina Y; Kurosaki M; Izumi N; Enomoto N; Kusakabe A; Kajiwara E; Itoh Y; Ide T; Tamori A; Matsubara M; Kawada N; Shirabe K; Tomita E; Honda M; Kaneko S; Nishina S; Suetsugu A; Hiasa Y; Watanabe H; Genda T; Sakaida I; Nishiguchi S; Takaguchi K; Tanaka E; Sugihara J; Shimada M; Kondo Y; Kawai Y; Kojima K; Nagasaki M; Tokunaga K; Tanaka Y;
Gastroenterology; 2017 May; 152(6):1383-1394. PubMed ID: 28163062
[TBL] [Abstract][Full Text] [Related]
2. TLL1 variants do not predict hepatocellular carcinoma development in HCV cirrhotic patients treated with direct-acting antivirals.
Degasperi E; Galmozzi E; Facchetti F; Farina E; D'Ambrosio R; Soffredini R; Iavarone M; Lampertico P
J Viral Hepat; 2019 Oct; 26(10):1233-1236. PubMed ID: 31177595
[TBL] [Abstract][Full Text] [Related]
3. TLL1 variant associated with development of hepatocellular carcinoma after eradication of hepatitis C virus by interferon-free therapy.
Iio E; Matsuura K; Shimada N; Atsukawa M; Itokawa N; Abe H; Kato K; Takaguchi K; Senoh T; Eguchi Y; Nomura H; Yoshizawa K; Kang JH; Matsui T; Hirashima N; Kusakabe A; Miyaki T; Fujiwara K; Matsunami K; Tsutsumi S; Iwakiri K; Tanaka Y
J Gastroenterol; 2019 Apr; 54(4):339-346. PubMed ID: 30382363
[TBL] [Abstract][Full Text] [Related]
4. A polymorphism in interferon L3 is an independent risk factor for development of hepatocellular carcinoma after treatment of hepatitis C virus infection.
Chang KC; Tseng PL; Wu YY; Hung HC; Huang CM; Lu SN; Wang JH; Lee CM; Chen CH; Tsai MC; Yen YH; Lin MT; Wu CK; Huang CC; Chen HH; Hu TH
Clin Gastroenterol Hepatol; 2015 May; 13(5):1017-24. PubMed ID: 25460552
[TBL] [Abstract][Full Text] [Related]
5. Assessment of TLL1 variant and risk of hepatocellular carcinoma in Latin Americans and Europeans.
Fu S; Karim D; Prieto J; Balderramo D; Ferrer JD; Mattos AZ; Arrese M; Carrera E; Oliveira J; Debes JD; Boonstra A
Ann Hepatol; 2024; 29(2):101181. PubMed ID: 37981236
[TBL] [Abstract][Full Text] [Related]
6. Combination of PNPLA3 and TLL1 polymorphism can predict advanced fibrosis in Japanese patients with nonalcoholic fatty liver disease.
Seko Y; Yamaguchi K; Mizuno N; Okuda K; Takemura M; Taketani H; Hara T; Umemura A; Nishikawa T; Moriguchi M; Yasui K; Kamaguchi M; Nishioji K; Mochizuki N; Kobayashi M; Mori K; Tanaka S; Matsuura K; Tanaka Y; Itoh Y
J Gastroenterol; 2018 Mar; 53(3):438-448. PubMed ID: 28744823
[TBL] [Abstract][Full Text] [Related]
7. Chitinase 3-like-1, Tolloid-like protein 1, and intergenic gene polymorphisms are predictors for hepatocellular carcinoma development after hepatitis C virus eradication by direct-acting antivirals.
Mangoud NOM; Ali SA; El Kassas M; Soror SH
IUBMB Life; 2021 Feb; 73(2):474-482. PubMed ID: 33347699
[TBL] [Abstract][Full Text] [Related]
8. HCV-Induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response.
Hamdane N; Jühling F; Crouchet E; El Saghire H; Thumann C; Oudot MA; Bandiera S; Saviano A; Ponsolles C; Roca Suarez AA; Li S; Fujiwara N; Ono A; Davidson I; Bardeesy N; Schmidl C; Bock C; Schuster C; Lupberger J; Habersetzer F; Doffoël M; Piardi T; Sommacale D; Imamura M; Uchida T; Ohdan H; Aikata H; Chayama K; Boldanova T; Pessaux P; Fuchs BC; Hoshida Y; Zeisel MB; Duong FHT; Baumert TF
Gastroenterology; 2019 Jun; 156(8):2313-2329.e7. PubMed ID: 30836093
[TBL] [Abstract][Full Text] [Related]
9. Genetic variation in the TLL1 gene is not associated with fibrosis in patients with metabolic associated fatty liver disease.
Bayoumi A; Jalil I; Metwally M; Adams LA; Aller R; García-Monzón C; Arias-Loste MT; Miele L; Petta S; Craxì A; Gallego-Durán R; Fischer J; Berg T; Qiao L; Liddle C; Bugianesi E; Romero-Gomez M; George J; Eslam M
PLoS One; 2020; 15(12):e0243590. PubMed ID: 33306709
[TBL] [Abstract][Full Text] [Related]
10. Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: A large-scale, long-term cohort study.
Nagaoki Y; Aikata H; Nakano N; Shinohara F; Nakamura Y; Hatooka M; Morio K; Kan H; Fujino H; Kobayashi T; Fukuhara T; Masaki K; Ono A; Nakahara T; Kawaoka T; Miki D; Tsuge M; Hiramatsu A; Imamura M; Takahashi S; Kawakami Y; Ochi H; Chayama K;
J Gastroenterol Hepatol; 2016 May; 31(5):1009-15. PubMed ID: 26584407
[TBL] [Abstract][Full Text] [Related]
11. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
[TBL] [Abstract][Full Text] [Related]
12. Association between Toll-Like Receptor 3 (TLR3) rs3775290, TLR7 rs179008, TLR9 rs352140 and Chronic HCV.
Mosaad YM; Metwally SS; Farag RE; Lotfy ZF; AbdelTwab HE
Immunol Invest; 2019 Apr; 48(3):321-332. PubMed ID: 30321082
[TBL] [Abstract][Full Text] [Related]
13. Tolloid-like 1 genetic variants determine fibrosis regression in chronic hepatitis C patients with curative antivirals.
Huang CF; Yeh ML; Huang CI; Lin ZY; Chen SC; Huang JF; Dai CY; Chuang WL; Chen JJ; Yu ML
Sci Rep; 2018 Oct; 8(1):15058. PubMed ID: 30305682
[TBL] [Abstract][Full Text] [Related]
14. Hepatic Fat-Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients With Cirrhotic HCV Treated With DAAs.
Degasperi E; Galmozzi E; Pelusi S; D'Ambrosio R; Soffredini R; Borghi M; Perbellini R; Facchetti F; Iavarone M; Sangiovanni A; Valenti L; Lampertico P
Hepatology; 2020 Dec; 72(6):1912-1923. PubMed ID: 32762045
[TBL] [Abstract][Full Text] [Related]
15. Association of serial serum major histocompatibility complex class I chain-related A measurements with hepatocellular carcinoma in chronic hepatitis C patients after viral eradication.
Huang CF; Wang SC; Yeh ML; Huang CI; Tsai PC; Lin ZY; Chen SC; Dai CY; Huang JF; Chuang WL; Chen A; Yu ML
J Gastroenterol Hepatol; 2019 Jan; 34(1):249-255. PubMed ID: 29932235
[TBL] [Abstract][Full Text] [Related]
16. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication.
van der Meer AJ; Feld JJ; Hofer H; Almasio PL; Calvaruso V; Fernández-Rodríguez CM; Aleman S; Ganne-Carrié N; D'Ambrosio R; Pol S; Trapero-Marugan M; Maan R; Moreno-Otero R; Mallet V; Hultcrantz R; Weiland O; Rutter K; Di Marco V; Alonso S; Bruno S; Colombo M; de Knegt RJ; Veldt BJ; Hansen BE; Janssen HLA
J Hepatol; 2017 Mar; 66(3):485-493. PubMed ID: 27780714
[TBL] [Abstract][Full Text] [Related]
17. Late development of hepatocellular carcinoma after viral clearance in patients with chronic hepatitis C: A need for continual surveillance.
Tong MJ; Theodoro CF; Salvo RT
J Dig Dis; 2018 Jul; 19(7):411-420. PubMed ID: 29889353
[TBL] [Abstract][Full Text] [Related]
18. Differences in background characteristics of patients with chronic hepatitis C who achieved sustained virologic response with interferon-free versus interferon-based therapy and the risk of developing hepatocellular carcinoma after eradication of hepatitis C virus in Japan.
Toyoda H; Tada T; Takaguchi K; Senoh T; Shimada N; Hiraoka A; Michitaka K; Ishikawa T; Kumada T
J Viral Hepat; 2017 Jun; 24(6):472-476. PubMed ID: 27983762
[TBL] [Abstract][Full Text] [Related]
19. Post-treatment levels of α-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy.
Oze T; Hiramatsu N; Yakushijin T; Miyazaki M; Yamada A; Oshita M; Hagiwara H; Mita E; Ito T; Fukui H; Inui Y; Hijioka T; Inada M; Katayama K; Tamura S; Yoshihara H; Inoue A; Imai Y; Hayashi E; Kato M; Miyagi T; Yoshida Y; Tatsumi T; Kasahara A; Hamasaki T; Hayashi N; Takehara T;
Clin Gastroenterol Hepatol; 2014 Jul; 12(7):1186-95. PubMed ID: 24321207
[TBL] [Abstract][Full Text] [Related]
20. Interleukin 28 Polymorphisms and Hepatocellular Carcinoma Development after Direct Acting Antiviral Therapy for Chronic Hepatitis C.
Simili A; Mazzella G; Ravaioli F; Festi D; Bacchi-Reggiani ML; Porro A; Bazzoli F; Azzaroli F
J Gastrointestin Liver Dis; 2019 Dec; 28(4):449-456. PubMed ID: 31826071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
